Neuregulin-1 acts through the ErbB signaling pathway to promote cardiomyocyte proliferation, angiogenesis, and cardiac repair, representing a promising therapeutic target for cardiovascular diseases.
NRG1 represents a potential therapeutic target for cardiac repair in various cardiovascular diseases through its regulation of the myocardial microenvironment.
NRG1 (Neuregulin-1) is an effective cardiomyocyte proliferator, secreted and released by endothelial vascular cells, and affects the cardiovascular system. It plays a major role in heart growth, proliferation, differentiation, apoptosis, and other cardiovascular processes. Numerous experiments have shown that NRG1 can repair the heart in the pathophysiology of atherosclerosis, myocardial infarction, ischemia reperfusion, heart failure, cardiomyopathy and other cardiovascular diseases. NRG1 can connect related signaling pathways through the NRG1/ErbB pathway, which form signal cascades to improve the myocardial microenvironment, such as regulating cardiac inflammation, oxidative stress, necrotic apoptosis. Here, we summarize recent research advances on the molecular mechanisms of NRG1, elucidate the contribution of NRG1 to cardiovascular disease, discuss therapeutic approaches targeting NRG1 associated with cardiovascular disease, and highlight areas for future research.
Wang et al. (Wed,) conducted a review in Cardiovascular disease. Neuregulin-1 (NRG1) was evaluated. Neuregulin-1 acts through the ErbB signaling pathway to promote cardiomyocyte proliferation, angiogenesis, and cardiac repair, representing a promising therapeutic target for cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: